Immunotoxin: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
| (One intermediate revision by the same user not shown) | |
(No difference)
| |
Latest revision as of 12:49, 18 March 2025
Immunotoxin is a type of biological therapy that uses a combination of antibody and toxin to specifically target and destroy cancer cells. The antibody part of the immunotoxin is designed to recognize and bind to a specific protein or antigen on the surface of cancer cells. The toxin part of the immunotoxin is a poisonous substance that kills the cells.
Structure[edit]
Immunotoxins are typically composed of two parts: a monoclonal antibody and a toxin. The monoclonal antibody is designed to specifically target a protein or antigen on the surface of cancer cells. The toxin is a poisonous substance, often derived from bacteria, plants, or animals, that can kill cells.
Mechanism of Action[edit]
Once the immunotoxin binds to the cancer cell, it is internalized and the toxin is released. The toxin then disrupts the cell's normal functions, leading to cell death. This targeted approach allows for the destruction of cancer cells while minimizing damage to healthy cells.
Types of Immunotoxins[edit]
There are several types of immunotoxins, including bacterial immunotoxins, plant immunotoxins, and animal immunotoxins. The type of immunotoxin used depends on the specific type of cancer being treated.
Uses[edit]
Immunotoxins are used in the treatment of various types of cancer, including leukemia, lymphoma, and certain types of solid tumors. They may be used alone or in combination with other treatments, such as chemotherapy or radiation therapy.
Side Effects[edit]
Like all cancer treatments, immunotoxins can cause side effects. These may include fever, chills, nausea, vomiting, and fatigue. In some cases, immunotoxins may also cause more serious side effects, such as allergic reactions or damage to healthy tissues.
Research[edit]
Research is ongoing to develop new and more effective immunotoxins. This includes efforts to improve the specificity of the monoclonal antibody component, to increase the potency of the toxin component, and to reduce the potential for side effects.



